Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2009, Article ID 345838, 10 pages
http://dx.doi.org/10.1155/2009/345838
Research Article

Leptin Enhances Synthesis of Proinflammatory Mediators in Human Osteoarthritic Cartilage—Mediator Role of NO in Leptin-Induced , IL-6, and IL-8 Production

1The Immunopharmacology Research Group, Medical School, University of Tampere and Research Unit, Tampere University Hospital, 33014 University of Tampere, Tampere, Finland
2Coxa Hospital for Joint Replacement, P.O. Box 652, 33101 Tampere, Finland

Received 12 March 2009; Accepted 4 June 2009

Academic Editor: Jan van Amsterdam

Copyright © 2009 Katriina Vuolteenaho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, “Positional cloning of the mouse obese gene and its human homologue,” Nature, vol. 372, no. 6505, pp. 425–432, 1994. View at Publisher · View at Google Scholar
  2. G. Matarese, S. Moschos, and C. S. Mantzoros, “Leptin in immunology,” The Journal of Immunology, vol. 174, no. 6, pp. 3137–3142, 2005. View at Google Scholar
  3. G. Frühbeck, “Intracellular signalling pathways activated by leptin,” Biochemical Journal, vol. 393, no. 1, pp. 7–20, 2006. View at Publisher · View at Google Scholar
  4. Q. L. Lam and L. Lu, “Role of leptin in immunity,” Cellular & Molecular Immunology, vol. 4, no. 1, pp. 1–13, 2007. View at Google Scholar
  5. M.-C. Park, S.-W. Lee, S.-T. Choi, Y.-B. Park, and S.-K. Lee, “Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis,” Scandinavian Journal of Rheumatology, vol. 36, no. 2, pp. 101–106, 2007. View at Publisher · View at Google Scholar
  6. E. Dennison and C. Cooper, “Osteoarthritis: epidemiology and classification,” in Rheumatology, M. C. Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt, and M. H. Weisman, Eds., pp. 1781–1791, Mosby, Toronto, Canada, 2003. View at Google Scholar
  7. H. Dumond, N. Presle, B. Terlain et al., “Evidence for a key role of leptin in osteoarthritis,” Arthritis and Rheumatism, vol. 48, no. 11, pp. 3118–3129, 2003. View at Publisher · View at Google Scholar
  8. N. Presle, P. Pottie, H. Dumond et al., “Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production,” Osteoarthritis and Cartilage, vol. 14, no. 7, pp. 690–695, 2006. View at Publisher · View at Google Scholar
  9. T. Simopoulou, K. N. Malizos, D. Iliopoulos et al., “Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism,” Osteoarthritis and Cartilage, vol. 15, no. 8, pp. 872–883, 2007. View at Publisher · View at Google Scholar
  10. K. Järvinen, K. Vuolteenaho, R. Nieminen, T. Moilanen, R. G. Knowles, and E. Moilanen, “Selective iNOS inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA cartilage as detected by protein antibody array,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 275–282, 2008. View at Google Scholar
  11. Y. Figenschau, G. Knutsen, S. Shahazeydi, O. Johansen, and B. Sveinbjörnsson, “Human articular chondrocytes express functional leptin receptors,” Biochemical and Biophysical Research Communications, vol. 287, no. 1, pp. 190–197, 2001. View at Publisher · View at Google Scholar
  12. M. Otero, J. J. Gomez Reino, and O. Gualillo, “Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-γ in human chondrocytes and ATDC5 chondrogenic cells,” Arthritis and Rheumatism, vol. 48, no. 2, pp. 404–409, 2003. View at Publisher · View at Google Scholar
  13. M. Otero, R. Lago, F. Lago, J. J. Reino, and O. Gualillo, “Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1,” Arthritis Research & Therapy, vol. 7, no. 3, pp. R581–591, 2005. View at Google Scholar
  14. D. Iliopoulos, K. N. Malizos, and A. Tsezou, “Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1616–1621, 2007. View at Publisher · View at Google Scholar
  15. K. Vuolteenaho, T. Moilanen, R. G. Knowles, and E. Moilanen, “The role of nitric oxide in osteoarthritis,” Scandinavian Journal of Rheumatology, vol. 36, no. 4, pp. 247–258, 2007. View at Google Scholar
  16. K. Vuolteenaho, T. Moilanen, N. Al-Saffar, R. G. Knowles, and E. Moilanen, “Regulation of the nitric oxide production resulting from the glucocorticoid-insensitive expression of iNOS in human osteoarthritic cartilage,” Osteoarthritis and Cartilage, vol. 9, no. 7, pp. 597–605, 2001. View at Publisher · View at Google Scholar
  17. D. L. Simmons, R. M. Botting, and T. Hla, “Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition,” Pharmacological Reviews, vol. 56, no. 3, pp. 387–437, 2004. View at Publisher · View at Google Scholar
  18. S. R. Goldring and M. B. Goldring, “The role of cytokines in cartilage matrix degeneration in osteoarthritis,” Clinical Orthopaedics and Related Research, no. 427, supplement, pp. S27–S36, 2004. View at Publisher · View at Google Scholar
  19. L. C. Green, D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum, “Analysis of nitrate, nitrite, and [N15]nitrate in biological fluids,” Analytical Biochemistry, vol. 126, no. 1, pp. 131–138, 1982. View at Google Scholar
  20. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Google Scholar
  21. R. F. Loeser, “Systemic and local regulation of articular cartilage metabolism: where does leptin fit in the puzzle?” Arthritis and Rheumatism, vol. 48, no. 11, pp. 3009–3012, 2003. View at Publisher · View at Google Scholar
  22. G. A. C. Murrell, D. Jang, and R. J. Williams, “Nitric oxide activates metalloprotease enzymes in articular cartilage,” Biochemical and Biophysical Research Communications, vol. 206, no. 1, pp. 15–21, 1995. View at Publisher · View at Google Scholar
  23. J.-P. Pelletier, V. Lascau-Coman, D. Jovanovic et al., “Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors,” Journal of Rheumatology, vol. 26, no. 9, pp. 2002–2014, 1999. View at Google Scholar
  24. H. J. Häuselmann, L. Oppliger, B. A. Michel, M. Stefanovic-Racic, and C. H. Evans, “Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture,” FEBS Letters, vol. 352, no. 3, pp. 361–364, 1994. View at Publisher · View at Google Scholar
  25. D. Taskiran, M. Stefanic-Racic, H. Georgescu, and C. Evans, “Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1,” Biochemical and Biophysical Research Communications, vol. 200, no. 1, pp. 142–148, 1994. View at Publisher · View at Google Scholar
  26. T. A. H. Järvinen, T. Moilanen, T. L. N. Järvinen, and E. Moilanen, “Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage,” Mediators of Inflammation, vol. 4, no. 2, pp. 107–111, 1995. View at Google Scholar
  27. M. Cao, A. Westerhausen-Larson, C. Niyibizi et al., “Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target,” Biochemical Journal, vol. 324, no. 1, pp. 305–310, 1997. View at Google Scholar
  28. F. J. Blanco, R. L. Ochs, H. Schwarz, and M. Lotz, “Chondrocyte apoptosis induced by nitric oxide,” American Journal of Pathology, vol. 146, no. 1, pp. 75–85, 1995. View at Google Scholar
  29. S. Hashimoto, K. Takahashi, D. Amiel, R. D. Coutts, and M. Lotz, “Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis,” Arthritis and Rheumatism, vol. 41, no. 7, pp. 1266–1274, 1998. View at Publisher · View at Google Scholar
  30. R. K. Studer, H. I. Georgescu, L. A. Miller, and C. H. Evans, “Inhibition of transforming growth factor β production by nitric oxide-treated chondrocytes: implications for matrix synthesis,” Arthritis and Rheumatism, vol. 42, no. 2, pp. 248–257, 1999. View at Publisher · View at Google Scholar
  31. J.-P. Pelletier, F. Mineau, P. Ranger, G. Tardif, and J. Martel-Pelletier, “The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation,” Osteoarthritis and Cartilage, vol. 4, no. 1, pp. 77–84, 1996. View at Publisher · View at Google Scholar
  32. K. Vuolteenaho, T. Moilanen, M. Hämäläinen, and E. Moilanen, “Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage: role of endogenous IL-1 inhibitors,” Scandinavian Journal of Rheumatology, vol. 32, no. 1, pp. 19–24, 2003. View at Publisher · View at Google Scholar
  33. R. K. Studer, E. Levicoff, H. Georgescu, L. Miller, D. Jaffurs, and C. H. Evans, “Nitric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IRβ tyrosine phosphorylation,” American Journal of Physiology, vol. 279, no. 4, pp. C961–C969, 2000. View at Google Scholar
  34. R. M. Clancy, P. F. Gomez, and S. B. Abramson, “Nitric oxide sustains nuclear factor κB activation in cytokine-stimulated chondrocytes,” Osteoarthritis and Cartilage, vol. 12, no. 7, pp. 552–558, 2004. View at Publisher · View at Google Scholar
  35. J.-P. Pelletier, D. Jovanovic, J. C. Fernandes et al., “Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase,” Arthritis and Rheumatism, vol. 41, no. 7, pp. 1275–1286, 1998. View at Publisher · View at Google Scholar
  36. J.-P. Pelletier, D. V. Jovanovic, V. Lascau-Coman et al., “Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level,” Arthritis and Rheumatism, vol. 43, no. 6, pp. 1290–1299, 2000. View at Publisher · View at Google Scholar
  37. C. Boileau, J. Martel-Pelletier, F. Moldovan et al., “The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide,” Arthritis and Rheumatism, vol. 46, no. 10, pp. 2637–2647, 2002. View at Publisher · View at Google Scholar
  38. W. B. van den Berg, F. van de Loo, L. A. B. Joosten, and O. J. Arntz, “Animal models of arthritis in NOS2-deficient mice,” Osteoarthritis and Cartilage, vol. 7, no. 4, pp. 413–415, 1999. View at Publisher · View at Google Scholar
  39. G. M. Raso, M. Pacilio, E. Esposito, A. Coppola, R. Di Carlo, and R. Meli, “Leptin potentiates IFN-γ-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1,” British Journal of Pharmacology, vol. 137, no. 6, pp. 799–804, 2002. View at Publisher · View at Google Scholar
  40. N. Mehebik, A.-M. Jaubert, D. Sabourault, Y. Giudicelli, and C. Ribiere, “Leptin-induced nitric oxide production in white adipocytes is mediated through PKA and MAP kinase activation,” American Journal of Physiology, vol. 289, no. 2, pp. C379–C387, 2005. View at Publisher · View at Google Scholar
  41. G. M. Raso, E. Esposito, A. Iacono et al., “Leptin induces nitric oxide synthase type II in C6 glioma cells: role for nuclear factor-?B in hormone effect,” Neuroscience Letters, vol. 396, no. 2, pp. 121–126, 2006. View at Publisher · View at Google Scholar
  42. A. Rodriguez, A. Fortuno, J. Gomez-Ambrosi, G. Zalba, J. Diez, and G. Frühbeck, “The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism,” Endocrinology, vol. 148, no. 1, pp. 324–331, 2007. View at Publisher · View at Google Scholar
  43. A. R. Amin, M. Attur, R. N. Patel et al., “Superinduction of cyclooxygenase-2 activity in human osteoarthritis- affected cartilage. Influence of nitric oxide,” Journal of Clinical Investigation, vol. 99, no. 6, pp. 1231–1237, 1997. View at Google Scholar
  44. J.-P. Pelletier, J. C. Fernandes, D. V. Jovanovic, P. Reboul, and J. Martel-Pelletier, “Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase,” Journal of Rheumatology, vol. 28, no. 11, pp. 2509–2519, 2001. View at Google Scholar
  45. R. Nieminen, S. Leinonen, A. Lahti et al., “Inhibitors of mitogen-activated protein kinases downregulate COX-2 expression in human chondrocytes,” Mediators of Inflammation, vol. 2005, no. 5, pp. 249–255, 2005. View at Publisher · View at Google Scholar
  46. K. M. Jordan, N. K. Arden, M. Doherty et al., “EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT),” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1145–1155, 2003. View at Publisher · View at Google Scholar
  47. R. D. Altman, M. C. Hochberg, R. W. Moskowitz, and T. J. Schnitzer, “Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update,” Arthritis and Rheumatism, vol. 43, no. 9, pp. 1905–1915, 2000. View at Publisher · View at Google Scholar
  48. O. Ogunwobi, G. Mutungi, and I. L. P. Beales, “Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation,” Endocrinology, vol. 147, no. 9, pp. 4505–4516, 2006. View at Publisher · View at Google Scholar
  49. S. Kaneko, T. Satoh, J. Chiba, C. Ju, K. Inoue, and J. Kagawa, “Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis,” Cytokines, Cellular and Molecular Therapy, vol. 6, no. 2, pp. 71–79, 2000. View at Google Scholar
  50. M. G. Attur, M. Dave, M. Akamatsu, M. Katoh, and A. R. Amin, “Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine,” Osteoarthritis and Cartilage, vol. 10, no. 1, pp. 1–4, 2002. View at Publisher · View at Google Scholar
  51. Y. E. Henrotin, D. D. De Groote, A. H. Labasse et al., “Effects of exogenous IL-1ß, TNFa, IL-6, and IL-8 and LIF on cytokine production by human articular chondrocytes,” Osteoarthritis and Cartilage, vol. 4, no. 3, pp. 163–173, 1996. View at Publisher · View at Google Scholar
  52. A. Matsukawa, T. Yoshimura, T. Maeda, S. Ohkawara, K. Takagi, and M. Yoshinaga, “Neutrophil accumulation and activation by homologous IL-8 in rabbits: IL- 8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo,” The Journal of Immunology, vol. 154, no. 10, pp. 5418–5425, 1995. View at Google Scholar
  53. C. R. Flannery, C. B. Little, C. E. Hughes, C. L. Curtis, B. Caterson, and S. A. Jones, “IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage,” Matrix Biology, vol. 19, no. 6, pp. 549–553, 2000. View at Publisher · View at Google Scholar
  54. C. J. Malemud, “Cytokines as therapeutic targets for osteoarthritis,” BioDrugs, vol. 18, no. 1, pp. 23–35, 2004. View at Publisher · View at Google Scholar
  55. J. Santos-Alvarez, R. Goberna, and V. Sanchez-Margalet, “Human leptin stimulates proliferation and activation of human circulating monocytes,” Cellular Immunology, vol. 194, no. 1, pp. 6–11, 1999. View at Publisher · View at Google Scholar
  56. J. Fukuda, K. Nasu, B. Sun, S. Shang, Y. Kawano, and I. Miyakawa, “Effects of leptin on the production of cytokines by cultured human endometrial stromal and epithelial cells,” Fertility and Sterility, vol. 80, supplement 2, pp. 783–787, 2003. View at Publisher · View at Google Scholar
  57. B. Mattioli, E. Straface, M. G. Quaranta, L. Giordani, and M. Viora, “Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming,” The Journal of Immunology, vol. 174, no. 11, pp. 6820–6828, 2005. View at Google Scholar
  58. G. Sweeney, “Leptin signalling,” Cellular Signalling, vol. 14, no. 8, pp. 655–663, 2002. View at Publisher · View at Google Scholar
  59. M. Otero, R. Lago, R. Gomez, F. Lago, J. J. Gomez-Reino, and O. Gualillo, “Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes,” Life Sciences, vol. 81, no. 19-20, pp. 1452–1460, 2007. View at Publisher · View at Google Scholar
  60. W. H. Yu, A. Walczewska, S. Karanth, and S. M. McCann, “Nitric oxide mediates leptin-induced luteinizing hormone-releasing hormone (LHRH) and LHRH and leptin-induced LH release from the pituitary gland,” Endocrinology, vol. 138, no. 11, pp. 5055–5058, 1997. View at Publisher · View at Google Scholar
  61. T. Brzozowski, P. C. Konturek, S. J. Konturek et al., “Leptin in gastroprotection induced by cholecystokinin or by a meal. Role of vagal and sensory nerves and nitric oxide,” European Journal of Pharmacology, vol. 374, no. 2, pp. 263–276, 1999. View at Publisher · View at Google Scholar
  62. G. Frühbeck, “Pivotal role of nitric oxide in the control of blood pressure after leptin administration,” Diabetes, vol. 48, no. 4, pp. 903–908, 1999. View at Google Scholar